Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: A status report and summary of an international meeting, 8-9 September 2008

Annals of Oncology

Volumn 20, Issue 9, 2009, Pages 1472-1482

  Cohen, J I ^a   Kimura, H ^b   Nakamura, S ^c   Ko, Y H ^d   Jaffe, Elaine S ^e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

^d Samsung Medical Center   (South Korea)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chronic active EBV infection; Diffuse large B cell lymphoma; Hemophagocytic syndrome; Hydroa vacciniforme; Immune senescence; Senile EBV positive lymphoproliferative disease; Systemic EBV positive lymphoproliferative disease

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BORTEZOMIB; BUTYRIC ACID; CHEMOKINE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; ETOPOSIDE; GAMMA INTERFERON; GANCICLOVIR; GEMCITABINE; IMMUNOGLOBULIN; INTERLEUKIN 2; RITUXIMAB; VALGANCICLOVIR; VALPROIC ACID;

ACUTE DISEASE; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CHRONIC ACTIVE EPSTEIN BARR VIRUS INFECTION; CHRONIC ACTIVE EPSTEIN BARR VIRUS INFECTION B LYMPHOCYTE TYPE; CHRONIC DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EPSTEIN BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISEASE; HUMAN; HYDROA VACCINIFORME; HYDROA VACCINIFORME LIKE LYMPHOMA; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; LYMPHATIC SYSTEM DISEASE; LYMPHOMATOID GRANULOMATOSIS; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; REVIEW; SENILE EPSTEIN BARR VIRUS LYMPHOPROLIFERATIVE DISEASE; SEVERE MOSQUITO BITE ALLERGY; STEM CELL TRANSPLANTATION; SYMPTOM; SYSTEMIC EPSTEIN BARR VIRUS T LYMPHOCYTE LYMPHOPROLIFERATIVE DISEASE OF CHILDHOOD; T LYMPHOCYTE; VIRUS INFECTION;

EID: 69849084076     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp064     Document Type: Review

References (68)

1. Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988; 157: 405-412.
2. Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-286.
3. Risdall RJ, McKenna RW, Nesbit ME et al. Virus-associated hemophagocytic syndrome: A benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979; 44: 993-1002.
4. Su IJ, Hsieh HJ, Lee CY. Histiocytic medullary reticulosis: A lethal form of primary EBV infection in young children in Taiwan [letter]. Lancet 1989; 1: 389.
5. Lay JD, Tsao CJ, Chen JY et al. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 1997; 100: 1969-1979.
6. Teruya-Feldstein J, Setsuda J, Yao X et al. MIP-1alpha expression in tissues from patients with hemophagocytic syndrome. Lab Invest 1999; 79: 1583-1590.
7. Oyama T, Ichimura K, Suzuki R et al. Senile EBV+ B-cell lymphoproliferative disorders: A clinicopathologic study of 22 patients. Am J Surg Pathol 2003; 27: 16-26.
8. Shimoyama Y, Oyama T, Asano N et al. Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: A mini review. J Clin Exp Hematop 2006; 46: 1-4.
9. Park S, Lee J, Ko YH et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 972-978.
10. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer 2008.
11. Bharadwaj M, Burrows SR, Burrows JM et al. Longitudinal dynamics of antigenspecific CD8+ cytotoxic T lymphocytes following primary Epstein-Barr virus infection. Blood 2001; 98: 2588-2589.
12. Silins SL, Sherritt MA, Silleri JM et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 2001; 98: 3739-3744.
13. Kanegane H, Wakiguchi H, Kanegane C et al. Viral interleukin-10 in chronic active Epstein-Barr virus infection. J Infect Dis 1997; 176: 254-257.
14. Teruya-Feldstein J, Jaffe ES, Burd PR et al. The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 1997; 90: 4099-5105.
15. Wong CK, Wong BCK, Chan KCA et al. Cytokine profile in fatal human immunodeficiency virus-tuberculosis Epstein-Barr virus-associated hemophagocytic syndrome. Arch Int Med 2007; 167: 1901-1903.
16. Tang YI, Liao C, Xu XJ et al. Detection of Th1/Th2 cytokines is useful for the quick and early diagnosis of hemophagocytic syndrome in children. Blood 2007; 110: 88B-89B.
17. Katano H, Ali MA, Patera AC et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood 2004; 103: 1244-1252.
18. Oyama T, Yamamoto K, Asano N et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: A study of 96 patients. Clin Cancer Res 2007; 13: 5124-5132.
19. Shimoyama Y, Yamamoto K, Asano N et al. Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: Special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci 2008; 99: 1085-1091.
20. Asano N, Yamamoto K, Tamaru J-I. Age-related EBV-associated B-cell lymphoproliferative disorders: Comparison with EBV-positive classical Hodgkin's lymphoma in elderly patients. Blood 2009; 113: 2629-2636.
21. Schrager J, Pittaluga S, Raffeld M, Jaffe ES. EBV reactivation syndromes in adults without known immunodeficiency. Mod Pathol 2009; 22 (Suppl 1): 285A.
22. Kojima M, Kashimura M, Itoh H et al. Epstein-Barr virus-related reactive lymphoproliferative disorders in middle-aged or elderly patients presenting with atypical features. A clinicopathological study of six cases. Pathol Res Pract 2007; 203: 587-591.
23. Guinee DJ, Jaffe E, Kingma D et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol 1994; 18: 753-764.
24. Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: Pathogenesis, pathology, and clinical implications. Cancer Surv 1997; 30: 233-248.
25. Wilson WH, Kingma DW, Raffeld M et al. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood 1996; 87: 4531-4537.
26. Dunleavy K, Janik J, Cohen J et al. Study of the treatment and biology of lymphomatoid granulomatosis (LYG); a rare EBV lymphoproliferative disorder. Ann Oncol 2005; 16 (Suppl 5): 59.
27. Fauci AS, Haynes BF, Costa J et al. Lymphomatoid granulomatosis: prospective clinical and therapeutic experience over 10 years. N Engl J Med 1982; 306: 68-74.
28. Katzenstein AA, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: A clinicopathologic study of 152 cases. Cancer 1979; 43: 360-373.
29. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 2006; 16: 251-261.
30. Kimura H, Morishima T, Kanegane H et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003; 187: 527-533.
31. Iwatsuki K, Ohtsuka M, Akiba H, Kaneko F. Atypical hydroa vacciniforme in childhood: From a smoldering stage to Epstein-Barr virus-associated lymphoid malignancy. J Am Acad Dermatol 1999; 40: 283-284.
32. Iwatsuki K, Xu Z, Takata M et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 1999; 140: 715-721.
33. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype. Distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious-mononucleosis-implications for the interindividual infection route of Epstein-Barr-virus. Blood 1995; 85: 744-750.
34. Isobe Y, Sugimoto K, Yang L et al. Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res 2004; 64: 2167-2174.
35. Tabiasco J, Vercellone A, Meggetto F et al. Acquisition of viral receptor by NK cells through immunological synapse. J Immunol 2003; 170: 5993-5998.
36. Kimura H, Hoshino Y, Hara S et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 2005; 191: 531-539.
37. Aoukaty A, Lee IF, Wu J, Tan R. Chronic active Epstein-Barr virus infection associated with low expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on natural killer cells. J Clin Immunol 2003; 23: 141-145.
38. Gotoh K, Ito Y, Shibata-Watanabe Y et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46: 1525-1534.
39. Sato E, Ohga S, Kuroda H et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol 2008; 83: 721-727.
40. Okamura T, Hatsukawa Y, Arai H et al. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet 2000; 356: 223-224.
41. Kawa K, Okamura T, Yasui M et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Crit Rev Oncol Hematol 2002; 44: 251-257.
42. Ohshima K, Kimura H, Yoshino T et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: Overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 2008; 58: 209-217.
43. Quintanilla-Martinez L, Kumar S, Fend F et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: A distinct clinicopathologic syndrome. Blood 2000; 96: 443-451.
44. Cho EY, Kim KH, Kim WS et al. The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: Incidence of disease entities by age groups. J Korean Med Sci 2008; 23: 185-192.
45. Su IJ, Lin DT, Hsieh HC et al. Fatal primary Epstein-Barr virus infection masquerading as histiocytic medullary reticulosis in young children in Taiwan. Hematol Pathol 1990; 4: 189-195.
46. Park S, Kim K, Kim WS et al. Systemic EBV+ T-cell lymphoma in elderly patients: Comparison with children and young adult patients. Virchows Arch 2008; 453: 155-163.
47. Chen G, Tai AK, Lin M et al. Increased proliferation of CD8+ T cells in SAP-deficient mice is associated with impaired activation-induced cell death. Eur J Immunol 2007; 37: 663-674.
48. Barrionuevo C, Anderson VM, Zevallos-Giampietri E et al. Hydroa-like cutaneous T-cell lymphoma: A clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002; 10: 7-14.
49. Katagiri Y, Mitsuhashi Y, Kondo S et al. Hydroa vacciniforme-like eruptions in a patient with chronic active EB virus infection. J Dermatol 2003; 30: 400-404.
50. Cho KH, Lee SH, Kim CW et al. Epstein-Barr virus-associated lymphoproliferative lesions presenting as a hydroa vacciniforme-like eruption: An analysis of six cases. Br J Dermatol 2004; 151: 372-380.
51. Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV-positive T-cell lymphoproliferative disorders of childhood. In Swerdlow SH, Campo E, Harris NL et al.: Poietic and Lymphoid Tissues, 4th edition. Lyon, France: International Agency for Research on Cancer 2008; 278-280.
52. Satoh M, Oyama N, Akiba H et al. Hypersensitivity to mosquito bites with natural-killer cell lymphocytosis: The possible implication of Epstein-Barr virus reactivation. Eur J Dermatol 2002; 12: 381-384.
53. Zhang Y, Nagata H, Ikeuchi T et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 2003; 121: 805-814.
54. Savoldo B, Huls MH, Liu Z et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100: 4059-4066.
55. Savoldo B, Goss JA, Hammer MM et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942-2949.
56. Louis CU, Straathof K, Bollard CM et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009; 113: 2442-2450.
57. Gottschalk S, Edwards OL, Sili U et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003; 101: 1905-1912.
58. Bollard CM, Straathof KC, Huls MH et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother 2004; 27: 317-327.
59. Hale GA, Bowman LC, Woodard JP et al. Allogeneic bone marrow transplantation for children with histiocytic disorders: Use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant 2003; 31: 981-986.
60. Cooper N, Rao K, Gilmour K et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006; 107: 1233-1236.
61. Hierro L, Diez-Dorado R, Diaz C et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl 2008; 14: 1185-1193.
62. He Y, Cai S, Zhang G et al. Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells. Virus Res 2008; 135: 175-180.
63. Perrine SP, Hermine O, Small T et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109: 2571-2578.
64. Feng WH, Israel B, Raab-Traub N et al. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002; 62: 1920-1926.
65. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006; 66: 8762-8769.
66. Srimatkandada P, Loomis R, Carbone R et al. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: A potential therapeutic approach to EBV-associated lymphoproliferative diseases. Eur J Haematol 2008; 80: 407-418.
67. Miyake A, Dewan MZ, Ishida T et al. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect 2008; 10: 748-756.
68. Nepomuceno RR, Balatoni CE, Natkunam Y et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472-4480.